MAPT and Alzheimer disease: In 2018, the National Institute on Aging-Alzheimer’s Association (NIA-AA) reported that the highest probability of identifying AD pathology is achieved by combining markers of Aβ (A) with p-Tau (T) pathology, which could be assessed in CSF [21].